tetano
Editor, Senior Moderator
J Clin Virol. 2020 Apr 29;128:104394. doi: 10.1016/j.jcv.2020.104394. [Epub ahead of print]
Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG.
Kr?ttgen A[SUP]1[/SUP], Cornelissen CG[SUP]2[/SUP], Dreher M[SUP]2[/SUP], Hornef M[SUP]3[/SUP], Im?hl M[SUP]1[/SUP], Kleines M[SUP]4[/SUP].
Author information
Abstract
BACKGROUND:
Facing the ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is an urgent need for serological assays identifying individuals with past coronavirus disease 2019 (COVID-19).
STUDY DESIGN:
Our study is the first to compare four new commercially available assays using 75 sera from patients tested positive or negative by SARS-CoV-2 PCR: the anti SARS-CoV-2 ELISA (IgG) (Euroimmun, Germany), the EDI New Coronavirus COVID-19 IgG ELISA, (Epitope diagnostics (EDI), USA), the recomWell SARS-CoV-2 IgG ELISA (Mikrogen, Germany), and the SARS-CoV-2 Virachip IgG (Viramed, Germany).
RESULTS:
We found a sensitivity of 86.4 %, 100 %, 86.4 %, and 77.3 % and a specificity of 96,2 %, 88,7 %, 100 %, and 100 % for the Euroimmun assay, the EDI assay, the Mikrogen assay, and the Viramed assay, respectively.
CONCLUSIONS:
Commercially available SARS-CoV-2 IgG assays have a sufficient specificity and sensitivity for identifying individuals with past SARS-CoV-2 infection.
Copyright ? 2020 Elsevier B.V. All rights reserved.
KEYWORDS:
COVID-19; ELISA; SARS-CoV-2
PMID:32416599DOI:10.1016/j.jcv.2020.104394
Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG.
Kr?ttgen A[SUP]1[/SUP], Cornelissen CG[SUP]2[/SUP], Dreher M[SUP]2[/SUP], Hornef M[SUP]3[/SUP], Im?hl M[SUP]1[/SUP], Kleines M[SUP]4[/SUP].
Author information
Abstract
BACKGROUND:
Facing the ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is an urgent need for serological assays identifying individuals with past coronavirus disease 2019 (COVID-19).
STUDY DESIGN:
Our study is the first to compare four new commercially available assays using 75 sera from patients tested positive or negative by SARS-CoV-2 PCR: the anti SARS-CoV-2 ELISA (IgG) (Euroimmun, Germany), the EDI New Coronavirus COVID-19 IgG ELISA, (Epitope diagnostics (EDI), USA), the recomWell SARS-CoV-2 IgG ELISA (Mikrogen, Germany), and the SARS-CoV-2 Virachip IgG (Viramed, Germany).
RESULTS:
We found a sensitivity of 86.4 %, 100 %, 86.4 %, and 77.3 % and a specificity of 96,2 %, 88,7 %, 100 %, and 100 % for the Euroimmun assay, the EDI assay, the Mikrogen assay, and the Viramed assay, respectively.
CONCLUSIONS:
Commercially available SARS-CoV-2 IgG assays have a sufficient specificity and sensitivity for identifying individuals with past SARS-CoV-2 infection.
Copyright ? 2020 Elsevier B.V. All rights reserved.
KEYWORDS:
COVID-19; ELISA; SARS-CoV-2
PMID:32416599DOI:10.1016/j.jcv.2020.104394